RUNX1T1 and central nervous system cancer: In glioma, RUNX1T1 has been viewed as a potential biomarker and possible target due to its interaction with Hypoxia-inducible factor 1α (HIF1α), which is closely related to the proliferation, survival, self-renewal, and invasiveness of glioma stem cells [59].